BetaStem Therapeutics Retains Conditas Biotechnology Group for Business Development and Corporate Strategy

SAN FRANCISCO--(BUSINESS WIRE)--

BetaStem Therapeutics, Inc., a pre-clinical biotechnology company focused on a curative treatment for diabetic retinopathy and diseases related to vascular damage, has retained Conditas Biotechnology Group, LLC for its services in the area of business development and corporate strategy.

Conditas, a boutique firm specializing in biotechnology outsourcing and business development for lean startups, is joining BetaStem as it moves toward pivotal clinical trials utilizing proprietary BetaStem technology.

Dr. Stephen Bartelmez, Founder and CEO of BetaStem Therapeutics said, "After our initial meeting, we knew that Conditas methods and professional connections would substantially assist BetaStem in our path to clinical trials. We look forward to working with Conditas to strengthen the BetaStem team.

Leland L. Johnson, Jr., Founder and Principal at The Conditas Group, commented, The BetaStem approach to treating diabetic retinopathy is compelling and achievable. It is our goal to engage the pharmaceutical industry and the investment community, as well as disease foundations, in order to accelerate BetaStems well-defined development plans and clinical milestones for its lead program.

Leland continued, Conditas utilizes our biotech business development model for the benefit of our collaborators, and in this case, for patients with diabetes living with serious complications from the disease.

Dr. Bartelmez added, Conditas is knowledgeable, friendly and easy to interact with. We see the BetaStem-Conditas partnership central to successfully developing our stem cell therapy programs.

About Conditas Biotechnology Group, LLC A specialty firm, we represent lean startups for science, business development and strategy in the areas of biotechnology, medical technology, IT, and social media. In another area of focus, Conditas represents small-niche biotechnology Contract Research Organizations (CROs) to their current and potential future customers from academia, biotech, and pharma. Conditas exercises professional networks for the benefit of clients, their customers, and ultimately, for patients and the public. Conditas was founded in 2010 and is based in Brookline, Massachusetts.

About BetaStem Therapeutics, Inc. Our fundamental vision is to cure diabetic retinopathy by repairing and regenerating damaged blood vessels in a patient's eye. The treatment is based on stem cells taken from a patient's own blood, bone marrow or cord blood, and then "activated" through a proprietary process. These activated CD34+ stem cells are the most potent of all cells, giving rise to millions of daughter cells capable of bringing about repair when brought into contact with the patients injured tissue. BetaStem was founded in 2006 and is based in Sausalito, California.

More:
BetaStem Therapeutics Retains Conditas Biotechnology Group for Business Development and Corporate Strategy